Karuna Therapeutics Provides Update on its Discovery Research Efforts
February 06 2020 - 7:00AM
Business Wire
Announces new strategic drug discovery
partnership with Charles River
Opens new office dedicated to drug discovery
and potential development of novel CNS therapeutics
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage
biopharmaceutical company committed to developing novel therapies
with the potential to transform the lives of people with disabling
and potentially fatal neuropsychiatric disorders and pain, today
announced an update on its research and development efforts in CNS.
To accommodate continued growth in its drug discovery efforts,
Karuna announced the opening of an office in Indianapolis, Indiana.
Additionally, Karuna announced a new multi-year drug discovery
collaboration with Charles River, a leading early-stage contract
research organization. The collaboration brings together decades of
experience, drug discovery capabilities and expertise at both
Charles River and Karuna.
“We are excited to be expanding our discovery efforts that will
broaden our early stage pipeline,” said Steve Paul, M.D., chief
executive officer, president, and chairman of Karuna. “Building on
the successful Phase 2 data of our lead product candidate KarXT, we
are now expanding our discovery efforts to pursue several novel CNS
targets to advance next generation treatments for patients with a
variety of disabling neuropsychiatric disorders. We aim to build a
pipeline of product candidates targeting key neurotransmitter
receptors to treat a broad range of disabling and debilitating CNS
disorders through highly differentiated pharmacology.”
To date, Karuna has employed state-of-the-art chemical
screening, hit to lead and lead optimization strategies and the
collaboration with Charles River will leverage their end-to-end
drug discovery and safety assessment platform to facilitate the
selection of optimized drug candidates to advance into clinical
development. “Both Karuna and Charles River have assembled an
unparalleled team of experienced ‘drug hunters’ with the potential
to discover the next generation of novel CNS therapeutics,” adds
Dr. Paul.
About Karuna
Karuna is a clinical-stage biopharmaceutical company committed
to developing and delivering first-in-class therapies with the
potential to transform the lives of people with CNS disorders –
which remain among the most disabling and potentially fatal
disorders worldwide. Galvanized by the understanding that today’s
neuropsychiatric and pain management patients deserve better,
Karuna’s mission is to harness the untapped potential of the
brain’s complex biology in pursuit of novel therapeutic pathways
that will advance the standard of care. For more information,
please visit karunatx.com.
Forward Looking Statements
This press release contains forward looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including among other things, the timing and completion of
the public offering, and other statements identified by words such
as “could,” “expects,” “intends,” “may,” “plans,” “potential,”
“should,” “will,” “would,” or similar expressions and the negatives
of those terms. Forward-looking statements are not promises or
guarantees of future performance, and are subject to a variety of
risks and uncertainties, many of which are beyond our control.
Actual results could differ materially from those anticipated in
such forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, market risks and
uncertainties and the satisfaction of customary closing conditions
for an offering of securities. These and other risks are described
under the heading “Risk Factors” in our most recent Quarterly
Report on Form 10-Q filed with the SEC and in other filings that
Karuna makes with the SEC. Our actual results could differ
materially from the results described in or implied by such
forward-looking statements. Forward-looking statements speak only
as of the date hereof, and, except as required by law, we undertake
no obligation to update or revise these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200206005300/en/
Investor: Chris Brinzey Westwicke, an ICR Company +1 339
970-2843 chris.brinzey@westwicke.com Media: Jenn Gordon
GlobalHealthPR +1 202 587-2580 jgordon@globalhealthpr.com
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024